Aug 22 (Reuters) - Swedish medical-equipment maker

Getinge said on Thursday it will acquire U.S.-based

organ transport company Paragonix Technologies for about $477

million.

Getinge will acquire all the issued and outstanding shares

of the privately-held Paragonix on a cash and debt-free basis,

adding that the initial payout related to the acquisition will

be financed through a bridge loan provided by Swedish bank SEB

Group.

The acquisition is expected to have a slightly negative

impact on Getinge's adjusted earnings per share in 2024, the

Gothenburg-based company said in a press release.

Paragonix Technologies, headquartered in Waltham,

Massachusetts, is a developer and manufacturer in the organ

transplant industry, focused on improving patient outcomes

through advanced organ preservation solutions, according to its

website.

Getinge, in July, had beat second-quarter earnings

forecasts, as its order intake rose despite some problems with

its packaging and heart products.